| [1] |
Waks AG, Winer EP. Breast cancer treatment: a review [J]. JAMA, 2019, 321(3): 288-300.
|
| [2] |
Park YH, Kim TY, Kim GM, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial [J]. Lancet Oncol, 2019, 20(12): 1750-1759.
|
| [3] |
Martin M, Zielinski C, Ruiz-Borrego M, et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase Ⅲ randomised controlled trial-PEARL [J]. Ann Oncol, 2021, 32(4): 488-499.
|
| [4] |
Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer [J]. N Engl J Med, 2016, 375(20): 1925-1936.
|
| [5] |
Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib plus letrozole in hormone receptor-positive (HR+), HER2-negative (HER2－), advanced breast cancer [J]. Ann Oncol, 2018, 29(7): 1541-1547.
|
| [6] |
Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer [J]. N Engl J Med, 2022, 386(10): 942-950.
|
| [7] |
Goetz MP, Toi M, Campone M, et al. Monarch 3: abemaciclib as initial therapy for advanced breast cancer [J]. J Clin Oncol, 2017, 35(32): 3638-3646.
|
| [8] |
Tripathy D, Im SA, Colleoni M et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial [J]. Lancet Oncol, 2018, 19(7): 904-915.
|
| [9] |
Lu YS, Im SA, Colleoni M, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre-and perimenopausal patients with HR+/HER2-advanced breast cancer in MONALEESA-7: a phase Ⅲ randomized clinical trial [J]. Clin Cancer Res, 2022, 28(5): 851-859.
|
| [10] |
Slamon DJ, Neven P, Chia S, et al. Phase Ⅲ randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3 [J]. J Clin Oncol, 2018, 36(24): 2465-2472.
|
| [11] |
Slamon DJ, Neven P, Chia S, et al. Overall survival (OS) results of the phase Ⅲ MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus), human epidermal growth factor 2-negative (HER2－) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB) [J]. Ann Oncol, 2019, 30(5): 856-857.
|
| [12] |
Albanell J, Martínez MT, Ramos M et al. Randomized phase Ⅱ study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER) [J]. Eur J Cancer, 2022, 161: 26-37.
|
| [13] |
Llombart-Cussac A, Pérez-García JM, Bellet M, et al. Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer: a randomized clinical trial [J]. JAMA Oncol, 2021, 7(12): 1791-1799.
|
| [14] |
Zhang J, Wang Q, Wang Q, et al. Mechanisms of resistance to estrogen receptor modulators in ER+/HER2-advanced breast cancer [J]. Cell Mol Life Sci, 2020, 77(4): 559-572.
|
| [15] |
Presti D, Quaquarini E. The PI3K/AKT/mTOR and CDK4/6 pathways in endocrine resistant HR+/HER2-metastatic breast cancer: biological mechanisms and new treatments [J]. Cancers (Basel), 2019, 11(9): 1242.
|
| [16] |
Nunnery SE, Mayer IA. Targeting the PI3K/AKT/mTOR pathway in hormone-positive breast cancer [J]. Drugs, 2020, 80(16): 1685-1697.
|
| [17] |
Miller TW, Rexer BN, Garrett JT, et al. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer [J]. Breast Cancer Res, 2011, 13(6): 224.
|
| [18] |
Andre F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer [J]. N Engl J Med, 2019, 380(20): 1929-1940.
|
| [19] |
Andre F, Ciruelos EM, Rubovszky G, et al. Alpelisib (ALP) 1 fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase Ⅲ SOLAR-1 trial [J]. Ann Oncol, 2018, 29(8): 709.
|
| [20] |
Juric D, Loibl S, Andre F, et al. Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR plus), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial [J]. J Clin Oncol, 2019, 37(15): 1038.
|
| [21] |
Andre F, Ciruelos EM, Juric D, et al. Overall survival (OS) results from SOLAR-1, a phase Ⅲ study of alpelisib (ALP) plus fulvestrant (FUL) for hormone receptor-positive (HR plus), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC) [J]. Ann Oncol, 2020, 31(4): S1150-1151.
|
| [22] |
Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study [J]. Lancet Oncol, 2021, 22(4): 489-498.
|
| [23] |
Rugo HS, Lerebours F, Ciruelos E, et al. PIK3CA-mutated (mut) hormone receptor-positive (HR plus), human epidermal growth factor receptor 2-negative (HER2－) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) plus aromatase inhibitor (AI): BYLieve study results [J]. J Clin Oncol, 2020, 38(15): 1006.
|
| [24] |
Rugo HS, Lerebours F, Juric D, et al. Alpelisib + letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2－) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results [J]. Cancer Res, 2021, 81(4_Suppl): PD2-07.
|
| [25] |
Bardia A, Hurvitz SA, Demichele A, et al. Phase Ⅰ/Ⅱ trial of exemestane, ribociclib, and everolimus in women with HR/HER2 advanced breast ccancer after progression on CDK4/6 inhibitors (TRINITI-1) [J]. Clin Cancer Res, 2021, 27(15): 4177-4185.
|
| [26] |
Wouters BJ, Delwel R. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia [J]. Blood, 2016, 127(1): 42-52.
|
| [27] |
Sermer D, Pasqualucci L, Wendel HG, et al. Emerging epigenetic-modulating therapies in lymphoma [J]. Nat Rev Clin Oncol, 2019, 16(8): 494-507.
|
| [28] |
Jiang ZF, Li W, Hu XC, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet Oncol, 2019, 20(6): 806-815.
|
| [29] |
O’Shaughnessy J, Schwartzberg L, Piccart M, et al. Results from CONTESSA: a phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2－，hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane [J]. Cancer Res, 2021, 81(4_Suppl): GS4-01.
|